Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)

China flag China · Delayed Price · Currency is CNY
5.97
+0.09 (1.53%)
Apr 29, 2026, 4:00 PM EDT
Market Cap3.95B -0.4%
Revenue (ttm)150.62M +15.4%
Net Income-201.43M
EPS-0.30
Shares Out656.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,943,920
Average Volume11,633,933
Open5.89
Previous Close5.88
Day's Range5.85 - 6.05
52-Week Range5.52 - 10.31
Beta0.65
RSI45.16
Earnings DateApr 29, 2026

About SHA:688373

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment... [Read more]

Sector Healthcare
Founded 2007
Employees 166
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688373
Full Company Profile

Financial Performance

In 2025, SHA:688373's revenue was 141.77 million, an increase of 8.83% compared to the previous year's 130.27 million. Losses were -241.61 million, -45.18% less than in 2024.

Financial Statements